Formation, signaling and occurrence of specialized pro-resolving lipid mediators—what is the evidence so far?
Formation of specialized pro-resolving lipid mediators (SPMs) such as lipoxins or resolvins
usually involves arachidonic acid 5-lipoxygenase (5-LO, ALOX5) and different types of …
usually involves arachidonic acid 5-lipoxygenase (5-LO, ALOX5) and different types of …
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation
S Burstein - Bioorganic & medicinal chemistry, 2015 - Elsevier
First isolated from Cannabis in 1940 by Roger Adams, the structure of CBD was not
completely elucidated until 1963. Subsequent studies resulted in the pronouncement that …
completely elucidated until 1963. Subsequent studies resulted in the pronouncement that …
Novel noninvasive approaches to the treatment of obesity: from pharmacotherapy to gene therapy
Recent insights into the pathophysiologic underlying mechanisms of obesity have led to the
discovery of several promising drug targets and novel therapeutic strategies to address the …
discovery of several promising drug targets and novel therapeutic strategies to address the …
The polypharmacological effects of cannabidiol
J Castillo-Arellano, A Canseco-Alba, SJ Cutler, F León - Molecules, 2023 - mdpi.com
Cannabidiol (CBD) is a major phytocannabinoid present in Cannabis sativa (Linneo, 1753).
This naturally occurring secondary metabolite does not induce intoxication or exhibit the …
This naturally occurring secondary metabolite does not induce intoxication or exhibit the …
Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects
EB Russo - British journal of pharmacology, 2011 - Wiley Online Library
Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964,
when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic …
when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic …
Pathogenesis of systemic sclerosis
D Pattanaik, M Brown, BC Postlethwaite… - Frontiers in …, 2015 - frontiersin.org
Systemic scleroderma (SSc) is one of the most complex systemic autoimmune diseases. It
targets the vasculature, connective tissue-producing cells (namely fibroblasts/myofibroblasts …
targets the vasculature, connective tissue-producing cells (namely fibroblasts/myofibroblasts …
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2
RG Pertwee, AC Howlett, ME Abood… - Pharmacological …, 2010 - ASPET
There are at least two types of cannabinoid receptors (CB1 and CB2). Ligands activating
these G protein-coupled receptors (GPCRs) include the phytocannabinoid Δ9 …
these G protein-coupled receptors (GPCRs) include the phytocannabinoid Δ9 …
In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease
Alzheimer's disease (AD) is a debilitating neurodegenerative disease that is affecting an
increasing number of people. It is characterized by the accumulation of amyloid-β and tau …
increasing number of people. It is characterized by the accumulation of amyloid-β and tau …
From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases
Cannabis sativa, commonly known as marijuana, contains a pool of secondary plant
metabolites with therapeutic effects. Besides Δ9-tetrahydrocannabinol that is the principal …
metabolites with therapeutic effects. Besides Δ9-tetrahydrocannabinol that is the principal …
International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands
In 2005, the International Union of Basic and Clinical Pharmacology Committee on Receptor
Nomenclature and Drug Classification (NC-IUPHAR) published a catalog of all of the human …
Nomenclature and Drug Classification (NC-IUPHAR) published a catalog of all of the human …